NSE · MEDICO
Medico Remedies Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹154 Cr with net profit ₹10 Cr — a 6.57% net margin, versus 5.64% the period before.
Shareholding
As of 2026-06-30
- Promoter61.38%
- Public38.54%
- FII0.08%
15,863 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.88× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Drug Manufacturers - Specialty & Generic · ranked #1 of 15 by market cap
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Medico Remedies Limited(this company) | — | 65.15 | 5.09 | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashMedico Remedies Limited (MEDICO) is listed with a market capitalization of Rs 317 Cr. The company reported revenue of Rs 153.63 Cr and a profit margin of 6.36%. Its earnings per share (EPS) stands at Rs 1.58. The stock's 52-week high is Rs 56.88 and its 52-week low is Rs 30.22.
Positives
- +The company's debt-to-equity ratio is low at 0.2.
- +Return on Capital Employed (ROCE) is 20.98%, indicating efficient use of capital.
- +Promoter pledge is 0% as of March 2026.
Negatives
- −Promoter shareholding has decreased from 73.34% in September 2021 to 61.38% in March 2026.
- −The company's dividend yield is 0%, indicating no dividends were paid.
- −Revenue growth information for the latest period is not available in the provided data.
Financial Performance
Revenue has shown growth over the past few years, increasing from Rs 123.42 Cr in March 2021 to Rs 153.63 Cr in March 2025. Net profit also increased from Rs 2.59 Cr in March 2021 to Rs 10.09 Cr in March 2025. Quarterly revenue for March 2026 was Rs 56.81 Cr, with a net profit of Rs 5.86 Cr.
Profitability & Returns
The company has a Return on Equity (ROE) of 17.38% and a Return on Capital Employed (ROCE) of 20.98%. The profit margin is reported at 6.36%. Earnings per share (EPS) for March 2025 was Rs 1.22, increasing from Rs 1 in March 2024. For the latest available annual data, EPS is Rs 1.58.
Balance Sheet
The debt-to-equity ratio is 0.2, indicating a relatively low level of debt. The book value per share is Rs 9.1. No specific data on total assets or liabilities is provided in the given information, limiting a comprehensive balance sheet assessment.
Ownership & Pledges
There are no pledged promoter shares as of March 2026. Promoter holding has decreased from 73.34% in September 2021 to 61.38% in March 2026.
Data as of — price: 2026-07-29 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.